Compare · LLY vs MURA
LLY vs MURA
Side-by-side comparison of Eli Lilly and Company (LLY) and Mural Oncology plc (MURA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MURA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $825.77B.
- Over the past year, LLY is down 1.3% and MURA is down 22.5% - LLY leads by 21.2 points.
- LLY has hit the wire 11 times in the past 4 weeks while MURA has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 4 for MURA).
- Company
- Eli Lilly and Company
- Mural Oncology plc
- Price
- $873.83+0.64%
- $2.03-0.49%
- Market cap
- $825.77B
- -
- 1M return
- -0.48%
- -2.87%
- 1Y return
- -1.31%
- -22.52%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 4
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Latest MURA
- Amendment: SEC Form SCHEDULE 13G/A filed by Mural Oncology plc
- SEC Form 15-12G filed by Mural Oncology plc
- SEC Form EFFECT filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form S-8 POS filed by Mural Oncology plc
- SEC Form POS AM filed by Mural Oncology plc
- SEC Form 4 filed by Director Hickey Benjamin
- Chief Executive Officer Loew Caroline returned 293,059 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Cuss Francis M